ReviewFrontiers in oncology2021
Viral Causality of Human Cancer and Potential Roles of Human Endogenous Retroviruses in the Multi-Omics Era: An Evolutionary Epidemiology Review.
Review in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Harnessing archaeogenetic for cancer therapy: bridging ancient DNA insights with modern therapeutic innovations.Clinical epigenetics · 2026Review
- Viral infection and thyroid disorders: a narrative review.Frontiers in microbiology · 2025Review
- The Potential Role of Virus Infection in the Progression of Thyroid Cancer.World journal of oncology · 2024Review
- Review
- Article
- A Clinicopathology Review and Update of Epstein-Barr Virus-Associated Mesenchymal Tumors.Cancers · 2023Review
- Insight into Oncogenic Viral Pathways as Drivers of Viral Cancers: Implication for Effective Therapy.Current oncology (Toronto, Ont.) · 2023Review
- Human endogenous retroviruses in cancer: Oncogenesis mechanisms and clinical implications.Journal of medical virology · 2023Review
- A Systems Biology Approach on the Regulatory Footprint of Human Endogenous Retroviruses (HERVs).Diseases (Basel, Switzerland) · 2022Article
- Epigenetics andInternational journal of molecular sciences · 2022Review
- EBV-associated diseases: Current therapeutics and emerging technologies.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Being responsible for almost 12% of cancers worldwide, viruses are among the oldest known and most prevalent oncogenic agents. The quality of the evidence for the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.